- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03714763
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
October 19, 2018 updated by: Zhebao Wu
The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of Nonfunctioning Pituitary Adenoma
To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists(DA).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Dopamine agonists are the first line therapy for prolactinoma,which are also effective in some cases of other subtypes of pituitary tumors.
It had been showed that dopamine agonists inhibit prolactin secretion by binding to and activating dopamine D2 receptors.
PET-MR combined MR images with PET function images is substantial to evaluate the expression of dopamine D2 receptors.The aim is to study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weiting Gu, MD
- Phone Number: 0086-13917778956
- Email: nowaiting1221@hotmail.com
Study Contact Backup
- Name: Zhebao Wu, Medical PhD
- Phone Number: 0086-021-64370045
- Email: zhebaowu@aliyun.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Normal serum pituitary hormone levels or mild increase of serum prolactin.
- Enhanced MRI shows a pituitary tumor and tumor diameter>1cm.
- Aged between 18 and 65 years old, either sex.
- Karnofsky performance status ≥ 70.
- The patient has signed the informed consent.
Exclusion Criteria:
- Patients concomitantly taking the psychotropic drugs.
- Patients with parkinson disease and is taking dopaminergic agents.
- Patients with pituitary adenoma who received Gamma knife treatment.
- Pregnant or lactating women.
- Patients with poor compliance, who cannot implement the program strictly.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline.
- Patients with claustrophobia. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug treatment
Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
|
Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months.
The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
|
Experimental: Surgery
Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
|
Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline on tumor volume
Time Frame: Up to 6 months]
|
Change from baseline on tumor volume measured by enhanced pituitary Magnetic Resonance Imaging(MRI). Record the tumor volume from enhanced pituitary MRI on every 3 month follow-up visit. |
Up to 6 months]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of visual acuity
Time Frame: Up to 6 months
|
Record the Visual acuity on every 3 month follow-up visit.
|
Up to 6 months
|
Change from visual field scale
Time Frame: Up to 6 months
|
2.Record the Visual field scale on every 3 month follow-up visit, 0 = normal, no vision loss; 1 = one quadrant vision loss; 2 = two quadrants of vision loss; 3 = three quadrants of vision loss; 4 = four quadrants of vision loss but retain a central tubular vision; 5 = blind
|
Up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Mukherjee J, Majji D, Kaur J, Constantinescu CC, Narayanan TK, Shi B, Nour MT, Pan ML. PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents. Synapse. 2017 Mar;71(3):10.1002/syn.21950. doi: 10.1002/syn.21950. Epub 2016 Nov 30.
- Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):447-60. doi: 10.1016/j.beem.2012.01.002. Epub 2012 May 22.
- Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008 Dec;15(4):905-15. doi: 10.1677/ERC-08-0181. Epub 2008 Sep 9.
- Su Z, Wang C, Wu J, Jiang X, Chen Y, Chen Y, Zheng W, Zhuge Q, Wu Z, Zeng Y. Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas. Neurol Sci. 2012 Apr;33(2):275-9. doi: 10.1007/s10072-011-0701-6. Epub 2011 Jul 12.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2018
Primary Completion (Anticipated)
November 30, 2021
Study Completion (Anticipated)
January 31, 2022
Study Registration Dates
First Submitted
October 14, 2018
First Submitted That Met QC Criteria
October 19, 2018
First Posted (Actual)
October 22, 2018
Study Record Updates
Last Update Posted (Actual)
October 22, 2018
Last Update Submitted That Met QC Criteria
October 19, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Adenoma
- Pituitary Neoplasms
- Pituitary Diseases
Other Study ID Numbers
- DD2RN-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
The individual patient Data would not be shared to the third facility, but the sponsor hasn't decided whether to share the individual patient date to the other related studies hold by himself in the future.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pituitary Adenoma
-
Asan Medical CenterUnknownPituitary ACTH Secreting AdenomaKorea, Republic of
-
Zhaoyun ZhangUnknownPituitary TumorChina
-
Tiburio TherapeuticsNot yet recruitingNon-Functional Pituitary Adenoma | Pituitary Tumor, Nonfunctioning
-
University of CopenhagenOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital and other collaboratorsCompletedAcromegaly Due to Pituitary AdenomaDenmark
-
Samsung Medical CenterNot yet recruitingAcromegaly Due to Pituitary AdenomaKorea, Republic of
-
Seoul National University HospitalNot yet recruitingNon-functioning Pituitary AdenomaKorea, Republic of
-
Vastra Gotaland RegionRecruitingNon-functioning Pituitary AdenomaSweden
-
Asan Medical CenterUnknownCavernous Sinus Invasion by Pituitary AdenomaKorea, Republic of
-
Zealand University HospitalNot yet recruitingNon-Functional Pituitary Adenoma
-
Novartis PharmaceuticalsCompleted
Clinical Trials on Drug treatment
-
CelltrionCompletedHealth, SubjectiveKorea, Republic of
-
Institut Cancerologie de l'OuestFondation ARC; University of Angers, GRANEMUnknownStage III Renal Cell Cancer | Metastatic Renal CancerFrance
-
University Children's Hospital BaselPermamed AG, Switzerland; Galvita AG, SwitzerlandCompleted
-
Chinese University of Hong KongNot yet recruitingClinical Outcomes
-
Medical University of South CarolinaWayne State University; National Institute on Minority Health and Health Disparities... and other collaboratorsCompleted
-
Shanghai HEP Pharmaceutical Co., Ltd.CompletedHepatitis B, ChronicChina
-
Shanghai HEP Pharmaceutical Co., Ltd.Completed
-
Psychiatric Hospital of AtticaThriassio General Hospital of ElefsinaCompletedSurgical Procedure, Unspecified | General Medical ConditionGreece
-
LEO PharmaCompleted
-
Chengdu JOYO pharma Co., Ltd.Guangzhou JOYO Pharma Co., LtdNot yet recruiting